Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present SIGA Technologies, Inc. (NASDAQ: SIGA).

Full DD Report for SIGA

You must become a subscriber to view this report.


Recent News from (NASDAQ: SIGA)

SIGA Technologies: A Buy For The Smallpox Treatment
SIGA Technologies Inc. ( SIGA ) announced that on May 1, the FDA Antimicrobial Drugs advisory committee has voted unanimously (17 to 0) that the benefits of TPOXX, a small molecule antiviral treatment for smallpox, outweigh its risks. In February, the FDA granted priority review to the a...
Source: SeekingAlpha
Date: May, 03 2018 17:02
Your Daily Pharma Scoop: IRWD Division, Jazz sNDA, Siga Adcomm
Analysis focus: IRWD Ironwood Pharma (IRWD) is going to split into two separate companies, both publicly traded, with one focusing on commercialization and the other on R&D. This move will happen in the first half of 2019 and be tax free to current shareholders. Ironwood’s lin...
Source: SeekingAlpha
Date: May, 03 2018 08:00
After Hours Gainers / Losers (05/01/2018)
Top gainers:   SIGA   +10.3% .  CYH +7.8% . SFLY +7.8% . ENPH   +7.4% . FTR   +6.8% . More news on: SIGA Technologies Inc., Community Health Systems, Inc., Shutterfly, Inc., Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 01 2018 17:36
FDA Ad Com backs SIGA's smallpox treatment; shares up 6% after hours
In a unanimous 17 - 0 vote, the FDA's Antimicrobial Drugs Advisory Committee voted in favor of approval for SIGA Technologies' (NASDAQ: SIGA ) TPOXX (tecovirimat) for the treatment of smallpox. More news on: SIGA Technologies Inc., Healthcare stocks news, Stocks on the move, Read mor...
Source: SeekingAlpha
Date: May, 01 2018 16:42
SIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX®
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced a favorable outcome of the U.S. Food and Drug...
Source: GlobeNewswire
Date: May, 01 2018 16:03
SIGA Technologies Stock Trading Halted Today; FDA Advisory Committee is Scheduled to Review New Drug Application of TPOXX®
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that Nasdaq has halted trading of the company...
Source: GlobeNewswire
Date: May, 01 2018 07:05
FDA Ad Com review for SIGA's tecovirimat May 1
The FDA's Antimicrobial Drugs Advisory Committee will meet tomorrow, May 1, to review SIGA Technologies' (NASDAQ: SIGA ) marketing application seeking approval for tecovirimat for the treatment of adults and children with smallpox disease caused by variola virus. More news on: SIGA Techn...
Source: SeekingAlpha
Date: April, 30 2018 08:50
SIGA Technologies Announces Relisting on Nasdaq
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that The Nasdaq Stock Market LLC has app...
Source: GlobeNewswire
Date: March, 20 2018 07:30
Emerging Developments: New Research on Siga Technologies and Tropicana Entertainment - A Look Ahead into 2018
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Siga Technologies Inc. (OTC PINK: SIGA) and Tropicana Entertainment Inc. (OTCQB: TPCA), including recent technical analysis and consolidated fundamental...
Source: ACCESSWIRE IA
Date: February, 27 2018 08:30
SIGA Technologies Announces FDA Accepts NDA and Grants Priority Review for Oral TPOXX to Treat Smallpox
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that the U.S. Food and Drug Administration ...
Source: GlobeNewswire
Date: February, 07 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-186.676.626.706.57442,798
2018-05-176.676.626.706.57442,798

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1415,19860,45225.1406Cover
2018-08-139,94537,31826.6493Cover
2018-08-1024,54173,18533.5328Cover
2018-08-0915,48636,99341.8620Short
2018-08-085,8116,97083.3716Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SIGA.


About SIGA Technologies, Inc. (NASDAQ: SIGA)

Logo for SIGA Technologies, Inc. (NASDAQ: SIGA)

We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is Tecovirimat, also known as ST , an orally administered antiviral drug that targets orthopoxviruses. While Tecovirimat is not yet licensed as safe or effective by the U.S. Food amp Drug Administration, it is a novel small molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield.

 

Contact Information

 

 

Current Management

  • Phillip L Gomez / CEO
  • Daniel J. Luckshire / CFO, EVP, EVP, Fin.
  • Dennis E. Hruby / CSO
  • Robin Abrams / General Counsel
  • James J. Antal /
  • Michael J. Bayer /
  • Thomas E. Constance /
  • Joseph W. Marshall, III /
  • Jeffrey B. Kindler /
  • Michael Plansky /
  • Eric Rose /
  • Paul G. Savas /

Current Share Structure

  • Market Cap: $456,450,225 - 03/16/2018
  • Authorized: 600,000,000 - 10/10/2016
  • Issue and Outstanding: 79,039,000 - 02/28/2018

 


Recent Filings from (NASDAQ: SIGA)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Registration of certain classes of securities 12(b) of the Securities Exchange Act
Filing Type: 8-A12BFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Registration of certain classes of securities 12(b) of the Securities Exchange Act
Filing Type: 8-A12BFiling Source: edgar
Filing Date: March, 20 2018
Filing Type: CERTFiling Source: edgar
Filing Date: March, 20 2018
Filing Type: CERTFiling Source: edgar
Filing Date: March, 20 2018

 

 


Daily Technical Chart for (NASDAQ: SIGA)

Daily Technical Chart for (NASDAQ: SIGA)


Stay tuned for daily updates and more on (NASDAQ: SIGA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SIGA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SIGA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SIGA and does not buy, sell, or trade any shares of SIGA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/